Characteristic | Patch-based monitoring (ACTIVE) (n = 43) | Short-duration Holter (CONTROL) (n = 47) | P value |
---|---|---|---|
Age, year | 70.7 ± 12.6 | 70.0 ± 13.9 | 0.82 |
Sex, no. (%) | |||
Male | 26 (60.5) | 29 (61.7) | 1.00 |
Female | 17 (39.5) | 18 (38.3) | |
Race or ethnic group, no. (%) | |||
Asian | 1 (2.3) | 2 (4.3) | 0.80 |
Black | 11 (25.6) | 10 (21.3) | |
White | 31 (72.1) | 35 (74.5) | |
Recruitment site, no. (%) | |||
King’s College Hospital | 12 (27.9) | 22 (46.8) | 0.08 |
Princess Royal University Hospital | 31 (72.1) | 25 (53.2) | |
Index event, no. (%) | |||
Stroke | 35 (81.4) | 43 (91.5) | 0.22 |
TIA | 8 (18.6) | 4 (8.5) | |
Prior stroke or TIA, no. (%) | 12 (27.9) | 7 (14.9) | 0.20 |
Score on NIH stroke scale (stroke patients)a | 2.3 ± 3.7 | 2.1 ± 2.6 | 0.90 |
Score on ABCD2 (TIA patients), no. | 4.1 ± 0.6 | 4.2 ± 0.8 | 0.87 |
Hypertension, no. (%) | 26 (60.5) | 30 (63.8) | 0.83 |
Diabetes, no. (%) | 10 (23.3) | 10 (21.3) | 1.00 |
CHADS2VASc2 score, no.b | 4.4 ± 1.2 | 4.3 ± 1.0 | 0.61 |
Ischaemic heart disease, no. (%) | 8 (18.6) | 5 (10.6) | 0.37 |
Hypercholesterolaemia, no. (%) | 17 (39.5) | 17 (36.2) | 0.83 |
Smoking status, no. (%) | |||
Ex-smoker | 12 (27.9) | 5 (10.6) | 0.27 |
Current smoker | 6 (14) | 10 (21.3) | |
Use of antiplatelet, no. (%)c | |||
None | 30 (69.8) | 33 (70.2) | 0.26 |
Aspirin | 5 (11.6) | 10 (21.3) | |
Clopidogrel | 6 (14.0) | 4 (8.5) | |
Aspirin and Clopidogrel | 2 (4.7) | 0 (0) | |
No. of days from index event to randomisation | 2.0 ± 1.2 | 1.9 ± 1.1 | 0.60 |